electroCore, Inc.

NasdaqCM ECOR

electroCore, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 12.95 M

electroCore, Inc. Cash and Short-Term Investments is USD 12.95 M for the quarter ending September 30, 2024, a -3.81% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

electroCore, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 13.46 M, a -37.81% change year over year.
electroCore, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 21.64 M, a -44.49% change year over year.
electroCore, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 39.00 M, a 50.17% change year over year.
electroCore, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 25.97 M, a -22.46% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: ECOR

electroCore, Inc.

CEO	Mr. Daniel S. Goldberger
IPO Date	June 22, 2018
Location	United States
Headquarters	200 Forge Way
Employees	68
Sector	Technology
Industries 3D Printing Biotechnology Clinical Trials Computers Drugstores & Retail Pharmacies Hardware & Electronics Medical Instruments Pharmaceuticals

Description

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Key trends

Past 5 years